InnoCare Doses First Healthy Volunteer in Clinical Trial of Novel VAV1 Degrader ICP-538
InnoCare has announced the successful dosing of the first healthy volunteer in a clinical trial for its innovative VAV1 degrader, ICP-538, marking a significant milestone in cancer treatment research in China. This trial aims to evaluate the safety and efficacy of the drug, which has the potential to transform therapeutic approaches to various cancers.